2011-2013年杭州地区20家医院口服降糖药用药分析  

Analysis of Oral Hypoglycemic Agents in Hospitals of Hangzhou Region during 2011-2013

作　　者：周燕军[1] 楼燕[1] 饶跃峰[1] 冯胜民[1] 张幸国[1] 

机构地区：[1]浙江大学附属第一医院药剂科,浙江杭州310003

出　　处：《药品评价》2014年第24期32-35,共4页Drug Evaluation

摘　　要：目的:了解目前杭州地区口服降糖药使用现状,分析用药特点及趋势。方法:根据杭州地区11家三甲医院和9家二甲医院2011-2013年的口服降糖药的销售金额、用药频度(DDDs)、日均费用(DDC)等数据,采用金额分析法和数据汇总法进行统计分析。结果:2011-2013年,杭州地区11家三甲医院和9家二甲医院门诊就诊糖尿病患者使用的口服降糖药销售总金额总用量及DDDs均呈逐年上升趋势。α-葡萄糖苷酶抑制药类销售额排序列第1位,销售金额前5的药品中DDDs排序列前3位是瑞格列奈、格列美脲、伏格列波糖。结论:口服降糖药应用比较合理。Objective： To study the utilization, medication characteristics and tendency of oral hypoglycemic agents in hospitals of Hangzhou region during 2011-2013. Methods： Data obtained from ll 3A hospitals and 9 2A hospitals in Hangzhou region were statistically analyzed, which included the sorts, amounts, purchase cost and DDDs of oral hypoglycemic agents from 2011 to 2013. Results： The total sales amount and DDDs of oral hypoglycemic drugs showed an upward trend year by year in 20 hospitals from 2011 to 2013. The sales amount of a-glucosidase inhibitor mounted the top for these three years. The top three drugs with the highest DDDs among the top 5 most saled ones were glimepiride, repaglinide and voglibose. Conclusion： Application of oral hypoglycemic agents in Hangzhou was reasonable.

关 键 词：杭州地区 口服降糖药 用药分析 DDDS DDC 

分 类 号：R956[医药卫生—药学]